Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

Area of Science:

• Tropical medicine
• Immunology
• Dermatology

Background:

• Localised cutaneous leishmaniasis (LCL) is a parasitic skin disease prevalent in tropical and subtropical regions.
• Current treatments, primarily antimonial chemotherapy, are associated with significant side effects and potential resistance.
• There is a need for safer, more accessible treatment options, especially for primary health services in rural areas.

Purpose of the Study:

• To compare the efficacy and safety of a novel combination immunotherapy (live BCG with killed leishmania promastigotes) against standard antimonial chemotherapy for LCL.

Main Methods:

• A randomised controlled trial was conducted involving 94 patients diagnosed with localised cutaneous leishmaniasis.
• Patients received either the combination immunotherapy (three vaccinations over 32 weeks) or a standard antimonial regimen (three 20-day courses of meglumine antimonate).
• Cure rates and adverse events were monitored and compared between the two groups.

Main Results:

• The immunotherapy group achieved a cure rate of 94%, comparable to the 94% cure rate observed in the chemotherapy group.
• Side effects in the immunotherapy group were infrequent (5.8%) and mild.
• Conversely, the chemotherapy group experienced frequent (52.4%) and often severe adverse events.

Conclusions:

• Combination immunotherapy presents a low-cost, low-risk alternative to traditional chemotherapy for treating localised cutaneous leishmaniasis.
• This immunotherapy approach is suitable for implementation by primary health services in resource-limited, rural settings.
• The findings support the potential of immunotherapy as a viable and safer treatment strategy for leishmaniasis.